Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference
Verastem, Inc. (Nasdaq:VSTM) announced its participation in the virtual H.C. Wainwright BioConnect 2021 Conference. The company's fireside chat will be available for on-demand listening starting January 11, 2021, at 6:00 a.m. EST. This event emphasizes Verastem's commitment to advancing new cancer treatments. The webcast can be accessed through the 'Media' section of the company’s website under 'Events & Presentations.'
Verastem focuses on developing small molecule drugs targeting critical cancer signaling pathways, including RAF/MEK and FAK inhibition.
- None.
- None.
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The fireside chat will be made available for on-demand listening beginning Monday, January 11, 2021 at 6:00 a.m. EST.
The webcast of the fireside chat will be available on the “Media” section of the Company’s website at www.verastem.com under “Events & Presentations”.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005286/en/
FAQ
When will Verastem's fireside chat take place at the H.C. Wainwright BioConnect 2021 Conference?
Where can I access the webcast of Verastem's fireside chat?
What is Verastem's focus in biopharmaceuticals?